Shamita Trivedi
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1114187903
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,441 of the $17,201 with a category attached, or 60.7%. 32 manufacturers reported payments, led by AbbVie at 35.4% of the total.
Across 702 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Dexcom, Inc.$2K
- Insulet Corporation$2K
- Tolmar Pharmaceuticals, Inc.$964
- Novo Nordisk$783
- AstraZeneca$706
- plus $4K from 26 others
What the payments were for
- Consulting fees$3,15018%
- Speaking & faculty fees$2,00012%
- Travel & lodging$1,4348%
- Food & beverage$10,44161%
- Education$1771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 94 | $6,095 |
| Dexcom, Inc. | 4 | $2,453 |
| Insulet Corporation | 144 | $1,749 |
| Tolmar Pharmaceuticals, Inc. | 99 | $964 |
| Novo Nordisk | 39 | $783 |
| AstraZeneca | 47 | $706 |
| Xeris Pharmaceuticals, Inc. | 52 | $627 |
| Endo Pharmaceuticals Inc. | 46 | $625 |
| Ascendis Pharma Endocrinology Inc | 36 | $499 |
| Embecta Corp. | 15 | $295 |
| Arbor Pharmaceuticals, Inc. | 17 | $288 |
| Lilly USA, LLC | 16 | $278 |
| Pfizer | 14 | $253 |
| Zealand Pharma US, Inc. | 14 | $235 |
| Amneal Pharmaceuticals LLC | 12 | $212 |
| Tolmar, Inc. | 7 | $154 |
| Medtronic(2 entities) | 6 | $135 |
| Tandem Diabetes Care, Inc. | 6 | $123 |
| Rhythm Pharmaceuticals, Inc. | 5 | $119 |
| Eton Pharmaceuticals, Inc. | 2 | $108 |
| Ipsen Biopharmaceuticals, Inc | 4 | $99 |
| Ultragenyx Pharmaceutical Inc. | 4 | $71 |
| Corcept Therapeutics | 3 | $66 |
| Azurity Pharmaceuticals, Inc. | 4 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Lifescan, Inc. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $27 |
| Companion Medical, Inc. | 2 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Abbott | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM CGM$2,417
- ARMOUR THYROID$929
- Omnipod$136
- Tresiba$124
How this compares
$17,201 in reported general payments places this provider in the 75th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.